Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/01/2016 02/02/2016 02/03/2016 02/04/2016 02/05/2016 Date
69.75(c) 64.91(c) 66.13(c) 67.51(c) 65.59(c) Last
1 344 029 1 135 559 1 428 128 1 458 748 1 316 866 Volume
+1.17% -6.94% +1.88% +2.09% -2.84% Change
More quotes
Financials ($)
Sales 2015 43,4 M
EBIT 2015 -282 M
Net income 2015 -278 M
Finance 2015 398 M
Yield 2015 -
Sales 2016 47,0 M
EBIT 2016 -330 M
Net income 2016 -330 M
Finance 2016 289 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
EV / Sales 2015 119x
EV / Sales 2016 112x
Capitalization 5 558 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
Sector
Biotechnology & Medical Research
Calendar
02/09 | 03:00pmPresentation
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
02/04 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Fourth Quarter a..
02/01 ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming February Investor..
02/01 ALNYLAM PHARMACEUTICALS : Completes Enrollment in APOLLO Phase 3 Study with Pati..
01/11 ALNYLAM PHARMACEUTICALS : Results of Operations and Financial Condition, Financi..
01/11 ALNYLAM PHARMACEUTICALS : Outlines 2016 Goals for RNAi Therapeutics Pipeline
01/04 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 34th Annual J.P. Morgan Hea..
2015 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Goldman Sachs "Healthcare C..
2015 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Goldman Sachs “Health..
More news
Sector news : Biotechnology & Medical Research - NEC
06:01pDJDrug Industry Launches Ad Campaign Aimed at Lawmakers
02/05 AMGEN : To Present At The Leerink Partners 5th Annual Global Healthcare Conferen..
02/05 SANOFI : Muzammil Mansuri is Sanofi’s new Executive Committee member
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
02/04 INSIDERINSIGHTS.COM DAILY ROUND UP 2 : Phillips 66, Dolby Labs, Liberty Interact..
02/01 Alnylam completes enrollment in late-stage study of patisiran in rare protein..
01/22 HEALTHCARE RATINGS ROUNDUP : Credit Suisse
01/14 Arbutus Biopharma Is Currently In Second Place In The Race For An HBV Cure
2015 MERRIMACK PHARMACEUTICALS : Grossly Undervalued


Comments 
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions